A rare case of nonenhancing primary central nervous system lymphoma mimic multiple sclerosis

References

1. ↵
   1. Gerstner ER,
   2. Batchelor TT

   (2010) Primary central nervous system lymphoma. Arch Neurol 67, 291–297.
2. ↵
   1. Zhao D,
   2. Qian L,
   3. Shen J,
   4. Liu X,
   5. Mei K,
   6. Cen J,
   7. et al.

   (2014) Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. J Cell Mol Med 18, 1081–1086.
3. ↵
   1. Haldorsen IS,
   2. Krakenes J,
   3. Krossnes BK,
   4. Mella O,
   5. Espeland A

   (2009) CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989-2003. AJNR Am J Neuroradiol 30, 744–751.
4. ↵
   1. Kawai N,
   2. Okubo S,
   3. Miyake K,
   4. Maeda Y,
   5. Yamamoto Y,
   6. Nishiyama Y,
   7. et al.

   (2010) Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings. Ann Nucl Med 24, 335–343.
5. ↵
   1. Terae S,
   2. Ogata A

   (1996) Nonenhancing primary central nervous system lymphoma. Neuroradiology 38, 34–37.
6. ↵
   1. Zhang D,
   2. Hu LB,
   3. Henning TD,
   4. Ravarani EM,
   5. Zou LG,
   6. Feng XY,
   7. et al.

   (2010) MRI findings of primary CNS lymphoma in 26 immunocompetent patients. Korean J Radiol 11, 269–277.
7. ↵
   1. Johnson BA,
   2. Fram EK,
   3. Johnson PC,
   4. Jacobowitz R

   (1997) The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 18, 563–572.
8. ↵
   1. Soussain C,
   2. Hoang-Xuan K

   (2009) Primary central nervous system lymphoma: an update. Curr Opin Oncol 21, 550–558.
9. ↵
   1. Kuker W,
   2. Nagele T,
   3. Korfel A,
   4. Heckl S,
   5. Thiel E,
   6. Bamberg M,
   7. et al.

   (2005) Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72, 169–177.
10. ↵
    1. Palmedo H,
    2. Urbach H,
    3. Bender H,
    4. Schlegel U,
    5. Schmidt-Wolf IG,
    6. Matthies A,
    7. et al.

    (2006) FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 33, 164–168.
11. ↵
    1. Yamaguchi S,
    2. Hirata K,
    3. Kobayashi H,
    4. Shiga T,
    5. Manabe O,
    6. Kobayashi K,
    7. et al.

    (2014) The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma. Ann Nucl Med 28, 603–609.